CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-05-17 | Hebel Henry VP, Product Development | Grant or award · Employee Stock Option (right to buy) | +43,000 | 43,000 | ||
| 2016-05-17 | GEORGIOU GEORGE Director | Grant or award · Director Stock Option (right to buy) | +24,000 | 24,000 | ||
| 2016-05-17 | Cox Russell J. Director | Grant or award · Director Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2016-04-12 | LILLY ELI & CO 10% owner | Conversion | +2,010,924 | 2,068,543 | ||
| 2016-04-12 | LILLY ELI & CO 10% owner | Conversion | +2,010,924 | 2,068,543 | ||
| 2016-04-12 | LILLY ELI & CO 10% owner | Purchase | +500,000 | $10.00 | $5.0M | 2,568,543 |
| 2016-04-12 | LILLY ELI & CO 10% owner | Conversion · Series A Preferred Stock | −890,476 | 0 | ||
| 2016-04-12 | LILLY ELI & CO 10% owner | Conversion · Series B Preferred Stock | −1,120,448 | 0 | ||
| 2016-04-12 | York Charles N II Chief Financial Officer and VP | Conversion | +1,324 | 8,828 | ||
| 2016-04-12 | York Charles N II Chief Financial Officer and VP | Conversion | +11,560 | 11,560 | ||
| 2016-04-12 | York Charles N II Chief Financial Officer and VP | Conversion · Series B Preferred Stock | −1,324 | 0 | ||
| 2016-04-12 | York Charles N II Chief Financial Officer and VP | Conversion · Series A Preferred Stock | −9,523 | 0 | ||
| 2016-04-12 | York Charles N II Chief Financial Officer and VP | Conversion · Series B Preferred Stock | −2,037 | 0 | ||
| 2016-04-12 | TYLER JOSEPH E VP, Manufacturing | Conversion | +31,260 | 42,428 | ||
| 2016-04-12 | TYLER JOSEPH E VP, Manufacturing | Conversion · Series A Preferred Stock | −22,857 | 0 | ||
| 2016-04-12 | TYLER JOSEPH E VP, Manufacturing | Conversion · Series B Preferred Stock | −8,403 | 0 | ||
| 2016-04-12 | Rowlinson Scott W VP, Research | Conversion | +11,204 | 11,204 | ||
| 2016-04-12 | Rowlinson Scott W VP, Research | Conversion · Series B Preferred Stock | −11,204 | 0 | ||
| 2016-04-12 | Quinn Anthony Director | Purchase | +10,000 | $10.00 | $100K | 10,000 |
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion | +2,010,924 | 2,010,924 |
Page 20 of 21 · 407 trades